Optimisation du contrôle local des cancers de la prostate à haut risque par les traitements multimodaux

Torre, 2015, Global cancer statistics, 2012, CACancer J Clin, 65, 87, 10.3322/caac.21262

Mohler, 2014, National Comprehensive Cancer Network. Prostate cancer, version 2.2014, J Natl Compr Cane Netw, 12, 686, 10.6004/jnccn.2014.0072

Rozet, 2018, French ccAFU guidelines - Update 2018-2020: Prostate cancer, Prog Urol, 28, S79, 10.1016/j.purol.2018.08.011

Pollack, 2002, Prostate cancer radiation dose response: Results of theM.D. Anderson phase III randomized trial, Int J Radiat Oncol Biol Phys, 53, 1097, 10.1016/S0360-3016(02)02829-8

Zelefsky, 2008, Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes, Int J Radiat Oncol Biol Phys, 71, 1028, 10.1016/j.ijrobp.2007.11.066

Spratt, 2013, Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 85, 686, 10.1016/j.ijrobp.2012.05.023

Bolla, 2002, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial, Lancet, 360, 103, 10.1016/S0140-6736(02)09408-4

Yossepowitch, 2008, Secondary therapy, metastatic progression, and cancer specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy, Eur Urol, 53, 950, 10.1016/j.eururo.2007.10.008

Bartek, 2013, Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer, Cancer Discov, 3, 1222, 10.1158/2159-8290.CD-13-0679

Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002

Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1

Widmark, 2009, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, Lancet, 373, 301, 10.1016/S0140-6736(08)61815-2

Warde, 2011, Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, Lancet, 378, 2104, 10.1016/S0140-6736(11)61095-7

Mottet, 2012, Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial, Eur Urol, 62, 213, 10.1016/j.eururo.2012.03.053

Bolla, 1997, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin, N Engl J Med., 337, 295, 10.1056/NEJM199707313370502

Pilepich, 2001, Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate, Int J Radiat Oncol Biol Phys, 50, 1243, 10.1016/S0360-3016(01)01579-6

Roach, 2008, Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610, J Clin Oncol, 26, 585, 10.1200/JCO.2007.13.9881

Denham, 2011, Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial, Lancet Oncol, 12, 451, 10.1016/S1470-2045(11)70063-8

Pilepich, 1997, Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group protocol 85-31, J Clin Oncol, 15, 1013, 10.1200/JCO.1997.15.3.1013

Pilepich, 2005, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31, Int J Radiat Oncol Biol Phys, 61, 1285, 10.1016/j.ijrobp.2004.08.047

D’Amico, 2015, Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer, JAMA, 314, 1291, 10.1001/jama.2015.8577

Horwitz, 2008, Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, J Clin Oncol, 26, 2497, 10.1200/JCO.2007.14.9021

Bolla, 2009, Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med, 360, 2516, 10.1056/NEJMoa0810095

Jones, 2011, Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 365, 107, 10.1056/NEJMoa1012348

Pisansky, 2015, Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910, J Clin Oncol, 33, 332, 10.1200/JCO.2014.58.0662

Thomsen, 2015, Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study, Eur J Cancer, 51, 1283, 10.1016/j.ejca.2015.03.021

Nabid, 2018, Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial, Eur Urol, 74, 432, 10.1016/j.eururo.2018.06.018

Roach, 2003, Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413, J Clin Oncol, 21, 1904, 10.1200/JCO.2003.05.004

Roach, 1993, Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 28, 33, 10.1016/0360-3016(94)90138-4

Roach, 2018, Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase3trial, Lancet Oncol., 19, 1504, 10.1016/S1470-2045(18)30528-X

Pommier, 2007, Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01, J Clin. Oncol, 25, 5366, 10.1200/JCO.2006.10.5171

Denham, 2014, Lancet Oncol, 15, 1076, 10.1016/S1470-2045(14)70328-6

Bolla, 2016, Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991, J Clin Oncol, 34, 1748, 10.1200/JCO.2015.64.8055

Zapatero, 2015, High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01 /05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol, 16, 320, 10.1016/S1470-2045(15)70045-8

Ito, 2016, Oncological outcomes in patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an openlabel, randomized, phase III trial, Eur Urol Suppl, 15, e677, 10.1016/S1569-9056(16)60679-6

Arcangeli, 2010, A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 78, 11, 10.1016/j.ijrobp.2009.07.1691

Arcangeli, 2012, Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 84, 1172, 10.1016/j.ijrobp.2012.02.049

Wilson, 2018, The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial, Int J Radiat Oncol Biol Phys, 100, 1179, 10.1016/j.ijrobp.2018.01.016

Incrocci, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 1061, 10.1016/S1470-2045(16)30070-5

Morris, 2015, ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer, J Clin Oncol, 33

Wedde, 2019, Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort, Radiother Oncol, 132, 211, 10.1016/j.radonc.2018.10.013

Shore, 2013, New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists, Prostate Cancer Prostatic Dis, 16, 7, 10.1038/pcan.2012.25

Ryan, 2013, Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096

Beer, 2014, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095

Fizazi, 2015, J Clin Oncol, 33, 723, 10.1200/JCO.2014.56.5119

Smith, 2018, Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546

James, 2017, Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Wilt, 2012, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, 367, 203, 10.1056/NEJMoa1113162

Bill-Axelson, 2011, Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 364, 1708, 10.1056/NEJMoa1011967

Briganti, 2015, Natural history of surgically treated high-risk prostate cancer, Urol Oncol, 33, 163.e7, 10.1016/j.urolonc.2014.11.018

Ward, 2005, Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent ofprostate-specific antigen testing: 15-year outcome, BJU Int, 95, 751, 10.1111/j.1464-410X.2005.05394.x

Roumiguié, 2014, External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer, BJU Int, 114, E113, 10.1111/bju.12763

Abdollah, 2015, Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients, Eur Urol, 68, 497, 10.1016/j.eururo.2015.06.020

Stranne, 2018, SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer, Scand J Urol, 26, 1

Thompson, 2009, Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial, J Urol, 181, 956, 10.1016/j.juro.2008.11.032

Wiegel, 2014, Adjuvant radiotherapy versus wait-and-seeafter radical prostatectomy: 10-year follow-up of the ARO96-02/AUO AP 09/95 trial, Eur Urol, 66, 243, 10.1016/j.eururo.2014.03.011

Bolla, 2012, Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911 ), Lancet, 380, 2018, 10.1016/S0140-6736(12)61253-7

Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostatespecific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X

Shipley, 2017, Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer, N Engl J Med, 376, 417, 10.1056/NEJMoa1607529

Pollack, 2018, Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORTTrial, Int J Radiat Oncol Biol Phys, 102, 1605, 10.1016/j.ijrobp.2018.08.052

Zhao, 2016, Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis, Lancet Oncol, 17, 1612, 10.1016/S1470-2045(16)30491-0

Dalela, 2017, Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model, J Clin Oncol, 35, 1982, 10.1200/JCO.2016.69.9918

Gore, 2017, Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study, Cancer, 123, 2850, 10.1002/cncr.30665

Kumar, 2006, Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst Rev, 10.1002/14651858.CD006019

Sayyid, 2017, A phase II, randomized, open-label study of neoadjuvant degarelix versus LHRH agonist in pros-tate cancer patients prior to radical prostatectomy, Clin Cancer Res, 23, 1974, 10.1158/1078-0432.CCR-16-1790

Messing, 2006, Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lym- phadenectomy, Lancet Oncol, 7, 472, 10.1016/S1470-2045(06)70700-8

Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720

Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318

Fizazi, 2015, Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial, Lancet Oncol, 16, 787, 10.1016/S1470-2045(15)00011-X

Rosenthal, 2009, Int J Radiat Oncol Biol Phys, 73, 672, 10.1016/j.ijrobp.2008.05.020

Rosenthal, 2019, Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial, J Clin Oncol, 37, 1159, 10.1200/JCO.18.02158

James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5

Kellokumpu-Lehtinen, 2018, A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13trial, J Clin Oncol, 36

Schweizer, 2013, Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials, Cancer, 119, 3610, 10.1002/cncr.28270

Ahlgren, 2018, Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial, Eur Urol, 73, 870, 10.1016/j.eururo.2018.01.012